US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

1:48U.S.Marineswiththe26thMarineExpeditionaryUnit(SpecialOperationsCapable)’s(MEU(SOC))MaritimeSpeci EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3




comprehensive

author：focus    Page View：854
Alastair Grant/AP

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

advertisement

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Kim Kardashian sparks debate on benefits of full
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies